Metabolic therapy encompasses therapeutic approaches that target metabolic dysfunction in neurodegenerative diseases. These strategies aim to improve brain energy metabolism, enhance mitochondrial function, and correct metabolic deficits that contribute to neuronal dysfunction and death. Key approaches include ketogenic diets, metabolic modulators, glucose metabolism enhancers, and fasting mimetics. This therapy is particularly relevant for Alzheimer's disease (AD) and Parkinson's disease (PD), both of which exhibit well-documented metabolic impairments. [1]
Neurodegenerative diseases are characterized by impaired cerebral glucose metabolism: [2]
Alzheimer's Disease: Regional brain hypometabolism (especially in posterior cingulate and hippocampus) precedes clinical symptoms by decades. Insulin resistance and impaired glucose transport contribute to energy deficits.
Parkinson's Disease: Complex I deficiency in mitochondria leads to impaired oxidative phosphorylation and ATP depletion in dopaminergic neurons.
Ketone Utilization: Provide alternative fuel (β-hydroxybutyrate) to glucose-deficient neurons
Mitochondrial Function: Enhance electron transport chain efficiency and ATP production
Insulin Sensitization: Improve insulin signaling and glucose uptake in the brain
Oxidative Stress Reduction: Decrease reactive oxygen species (ROS) production
Neuroinflammation Modulation: Reduce inflammatory responses through metabolic pathways
Autophagy Enhancement: Activate metabolic pathways that clear misfolded proteins
The ketogenic diet (KD) mimics fasting metabolism by shifting energy production from glucose to ketone bodies: [3]
| Compound | Dose | Status | [4]
|----------|------|--------| [5]
| AC-1202 (AXONA) | 20-30g daily | FDA medical food | [6]
| Ketone ester | 25-50g daily | Clinical trials | [7]
| MCT oil | 20-60g daily | Widely available | [8]
| Trial | Intervention | Phase | Key Findings | [9]
|-------|--------------|-------|--------------| [10]
| NCT00670146 | Ketogenic diet | Phase 2 | Improved cognition in mild cognitive impairment |
| NCT02531438 | MCT oil (Axona) | Phase 3 | Significant cognitive improvement in APOE4- patients |
| NCT03400124 | Ketone ester | Phase 1/2 | Safety established; biomarker changes |
| NCT04237411 | Fasting mimetic | Phase 2 | Recruiting |
| Trial | Intervention | Phase | Key Findings |
|---|---|---|---|
| NCT03963206 | Ketogenic diet | Phase 2 | Motor symptoms improvement (23% UPDRS reduction) |
| NCT05237505 | MCT supplementation | Phase 2 | Ongoing |
| NCT05485640 | Metabolic modulator | Phase 1 | Safety assessment |
Effective patient selection requires metabolic profiling:
Henderson et al. Study of the Ketogenic Agent AC-1202 (2009). 2009. ↩︎
Krikorian et al. Ketogenic diet for MCI (2012). 2012. ↩︎
Pawelzik et al. Ketogenic diet in Parkinson's disease (2022). 2022. ↩︎
Cunnane et al. Brain energy metabolism in AD (2020). 2020. ↩︎
Van der Auwera et al. Ketogenic diet effects on neurodegeneration (2005). 2005. ↩︎
Freeman et al. [Ketogenic diet in neurological disorders (2014)](https://doi.org/10.1016/S1474-4422(14). 2014. ↩︎
Mattson et al. Energy intake and excitability (2018). 2018. ↩︎
Phillips et al. Low-carbohydrate diets for AD (2018). 2018. ↩︎
Taylor et al. Metabolic therapy for PD (2021). 2021. ↩︎